CYTOF — Altamira Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Auris Medical Holding Files For Shelf Of Up To 2.2 Mln Common Shares By Selling Stockholder
Brief: Auris Says Advancing Phase 2 Trial With AM-125 In Acute Vertigo Based On Positive Interim Data
Brief: Auris Medical Launches Development Of Drug-Free Nasal Spray For Protection Against Airborne Pathogens And Allergens
Brief: Auris Medical Announces Positive Interim Data From Travers Phase 2 Study With Am-125 In Vertigo
Brief: Auris Medical Regains Listing Compliance With Nasdaq Minimum Bid Requirement
Brief: Auris Medical Says Enrollment In First Part Of Travers Phase 2 Study Completed
Brief: Auris Medical Announces Positive Top-Line Data From Am-201 Phase 1B Study In Antipsychotic-Induced Weight Gain
Brief: Auris Medical Holding Received A Letter From The Listings Qualifications Department Of Nasdaq
Brief: Auris Medical Says Lincoln Park To Purchase From Co Up To $10 Million Of Common Shares
Brief: Auris Medical Says Phase 2 Trial With Intranasal Betahistine For Treatment Of Acute Vertigo Progressing Towards Interim Analysis
Brief: Auris Medical Says Outbreak Has Delayed Enrollment Into Phase 2 Trial With AM-125
Brief: Auris Medical Provides Update On Ongoing Clinical Trials With Intranasal Betahistine
Brief: Auris Medical Announces Notice Of Allowance For European Patent Application
Brief: Auris Medical Announces Formation Of New Subsidiary For Development Projects In Tinnitus And Hearing Loss
Brief: Auris Medical Announces Positive Interim Results From AM-201 Phase 1B Study In Antipsychotic-Induced Weight Gain
Brief: Auris Medical Holding Appoints Elmar Schärli As New CFO, Effective Nov. 1, 2019
Polyphor reinvents itself after abandoning antibiotic trial
Brief: Auris Medical Announces Randomization Of First Patient In Am-125 Phase 2 Trial In Acute Vertigo
Brief: Thomas Meyer Reports 14.4% Stake In Auris Medical Holding Ltd As Of June 3, 2019 - SEC Filing